Purchase

Recombinant Human PTPRF protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg6919


Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human PTPRF protein Asp30-Trp1263 (Accession# P10586-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 5792
Accession P10586-1
PredictedSize 162 kDa
SDS-PAGE 40-45 kDa, 120-140 kDa and 150-200 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

PTPRF (Protein Tyrosine Phosphatase Receptor Type F) is a receptor protein tyrosine phosphatase, also known as LAR. PTPRF is a transmembrane protein with extracellular domain, transmembrane domain and two intracellular catalytic domains in series. It is located in the cell membrane and participates in the interaction between cells or cell matrix. It is widely expressed in many tissues, including fat, skin, heart, lung, liver, kidney, pancreas, small intestine, colon, brain, skeletal muscle, spleen, peripheral white blood cells and so on. The protein plays an important role in regulating a variety of cell processes, including cell growth, differentiation, mitotic cycle and carcinogenic transformation. In the insulin-responsive tissues of obese and insulin-resistant individuals, the expression level of PTPRF is increased, which may contribute to the pathogenesis of insulin resistance. PTPRF showed expression changes in many cancers, such as breast cancer, thyroid cancer, non-small cell lung cancer and so on. In gastric adenocarcinoma, PTPRF, as a new tumor suppressor, plays a role by inactivating ERK1/2 signaling pathway.

References:

1.Konishi, N et al. British journal of cancer vol. 88,8 (2003): 1223-8. 2.Soulières, Denis et al. Journal of thoracic oncology vol. 10,9 (2015): 1364-1369. 3.Tian, Xiang'an et al. OncoTargets and therapy vol. 11 7795-7803. 2 Nov. 2018, doi:10.2147/OTT.S178152


||
New chat

Able

正在加载,请稍候...